Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5462 in Stable Patients with Chronic Heart Failure
2023-510148-19-00Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing AZD5462 (dose-ranging) + standard of care with Placebo + standard of care (2 arms). Started Jul 2024; status: completed.
02
Drugs
AZD5462
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on 2023-510148-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510148-19-00.